Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

rabeprazole sodium

&times

Overview

What is AcipHex?

The active ingredient in ACIPHEX delayed-release tablets is rabeprazole sodium, which is a proton pump inhibitor.  It is a substituted benzimidazole known chemically as 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1benzimidazole sodium salt.  It has an empirical formula of CHNNaOS and a molecular weight of 381.42.  Rabeprazole sodium is a white to slightly yellowish-white solid.  It is very soluble in water and methanol, freely soluble in ethanol, chloroform, and ethyl acetate and insoluble in ether and n-hexane.  The stability of rabeprazole sodium is a function of pH; it is rapidly degraded in acid media, and is more stable under alkaline conditions.  The structural figure is:

Figure 1

ACIPHEX is available for oral administration as delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.

Inactive ingredients of the 20 mg tablet are carnauba wax, crospovidone, diacetylated monoglycerides, ethylcellulose, hydroxypropyl cellulose, hypromellose phthalate, magnesium stearate, mannitol, propylene glycol, sodium hydroxide, sodium stearyl fumarate, talc, and titanium dioxide.  Iron oxide yellow is the coloring agent for the tablet coating.  Iron oxide red is the ink pigment.



What does AcipHex look like?



What are the available doses of AcipHex?

Delayed-Release Tablets:  20 mg ().

What should I talk to my health care provider before I take AcipHex?

Pediatric Use

     

How should I use AcipHex?

ACIPHEX delayed-release tablets are indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD).  For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of ACIPHEX may be considered.

Table 1 shows the recommended dosage of ACIPHEX delayed-release tablets in adults and adolescent patients 12 years of age and older. The use of ACIPHEX delayed-release tablets is not recommended for use in pediatric patients 1 year to less than 12 years of age because the lowest available tablet strength (20 mg) exceeds the recommended dose for these patients. Use another rabeprazole formulation for pediatric patients 1 year to less than 12 years of age.

* For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of ACIPHEX may be considered.** If symptoms do not resolve completely after 4 weeks, an additional course of treatment may be considered. *** Most patients heal within 4 weeks; some patients may require additional therapy to achieve healing.

Administration

Instruction

s


What interacts with AcipHex?

Sorry No Records found


What are the warnings of AcipHex?

Sorry No Records found


What are the precautions of AcipHex?

Sorry No Records found


What are the side effects of AcipHex?

Sorry No records found


What should I look out for while using AcipHex?

• ACIPHEX is contraindicated in patients with known hypersensitivity to rabeprazole, substituted benzimidazoles, or to any component of the formulation.  Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute interstitial nephritis, and urticaria .

• PPIs, including ACIPHEX, are contraindicated with rilpivirine-containing products .

• For information about contraindications of antibacterial agents (clarithromycin and amoxicillin) indicated in combination with ACIPHEX delayed-release tablets, refer to the section of their package inserts.


What might happen if I take too much AcipHex?

Seven reports of accidental overdosage with rabeprazole have been received.  The maximum reported overdose was 80 mg.  There were no clinical signs or symptoms associated with any reported overdose.  Patients with Zollinger-Ellison syndrome have been treated with up to 120  mg rabeprazole once daily.  No specific antidote for rabeprazole is known.  Rabeprazole is extensively protein bound and is not readily dialyzable.

In the event of overdosage, treatment should be symptomatic and supportive.  

If over-exposure occurs, call your Poison Control Center at 1-800-222-1222 for current information on the management of poisoning or overdosage.


How should I store and handle AcipHex?

Store protected from light in the aluminum pouch at controlled room temperature (20° to 25°C [68° to 77°F]); excursions permitted to 15°to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Store at controlled room temperature (20° to 25°C [68° to 77°F]); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Store protected from light in the aluminum pouch at controlled room temperature (20° to 25°C [68° to 77°F]); excursions permitted to 15°to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Store at controlled room temperature (20° to 25°C [68° to 77°F]); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. ACIPHEX 20 mg is supplied as delayed-release light yellow enteric-coated tablets.  The name and strength, in mg, (ACIPHEX 20) is imprinted on one side.       Bottles of 30 (NDC 62856-243-30)       Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) .  Protect from moisture.ACIPHEX 20 mg is supplied as delayed-release light yellow enteric-coated tablets.  The name and strength, in mg, (ACIPHEX 20) is imprinted on one side.       Bottles of 30 (NDC 62856-243-30)       Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) .  Protect from moisture.ACIPHEX 20 mg is supplied as delayed-release light yellow enteric-coated tablets.  The name and strength, in mg, (ACIPHEX 20) is imprinted on one side.       Bottles of 30 (NDC 62856-243-30)       Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) .  Protect from moisture.ACIPHEX 20 mg is supplied as delayed-release light yellow enteric-coated tablets.  The name and strength, in mg, (ACIPHEX 20) is imprinted on one side.       Bottles of 30 (NDC 62856-243-30)       Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) .  Protect from moisture.


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Rabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H-receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H, KATPase at the secretory surface of the gastric parietal cell.  Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor.  Rabeprazole blocks the final step of gastric acid secretion.

In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfenamide.  When studied , rabeprazole is chemically activated at pH 1.2 with a half-life of 78 seconds.  It inhibits acid transport in porcine gastric vesicles with a half-life of 90 seconds.

Non-Clinical Toxicology
• ACIPHEX is contraindicated in patients with known hypersensitivity to rabeprazole, substituted benzimidazoles, or to any component of the formulation.  Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute interstitial nephritis, and urticaria .

• PPIs, including ACIPHEX, are contraindicated with rilpivirine-containing products .

• For information about contraindications of antibacterial agents (clarithromycin and amoxicillin) indicated in combination with ACIPHEX delayed-release tablets, refer to the section of their package inserts.

The renal effects of nephrotoxic compounds may be potentiated by carboplatin.

In adults, symptomatic response to therapy with ACIPHEX does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing in adult patients who have a suboptimal response or an early symptomatic relapse after completing treatment with a PPI.

The following serious adverse reactions are described below and elsewhere in labeling:

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).